Why the NHS leaves a gap for younger hip patients

For many patients in their thirties, forties, or early fifties, the answer to a painful hip is not yet total replacement — but that is precisely where the NHS pathway runs out of options. Articular cartilage, the smooth tissue lining the femoral head and the acetabular socket, has no blood supply. Once a full-thickness focal defect develops — whether from a femoroacetabular impingement (FAI), a sporting injury, or repeated stress — the body cannot repair it spontaneously. The damage is clinically permanent without intervention.

The NHS, for all its breadth, has no commissioned pathway bridging that gap for the hip. Conservative management — physiotherapy, anti-inflammatory medication, and steroid injections — remains the NHS starting point. When conservative care is exhausted, the next funded step is total hip replacement. For younger or physically active patients with a focal defect who are not yet appropriate candidates for replacement, there is no publicly funded middle ground. This is a commissioning gap, not a reflection of clinical indifference.

Four joint-preserving techniques are available privately in the UK to fill that gap: ChondroFiller injection, AMIC (Autologous Matrix-Induced Chondrogenesis), OATS (Osteochondral Autograft Transfer), and OCA (Osteochondral Allograft). Each addresses different defect sizes and clinical circumstances, and each sits entirely outside NHS funding for the hip. The sections below explain how they work, who they suit, and what they cost.

ChondroFiller injection: the outpatient collagen scaffold

Sitting at the least invasive end of the spectrum, ChondroFiller injection requires no operating theatre, no general anaesthetic, and no overnight admission. It is delivered as an ultrasound-guided outpatient procedure: a liquid type-I collagen matrix — manufactured by Meidrix Biomedicals GmbH in Germany and CE-marked as a Class III medical device — is injected directly into the focal cartilage defect under image guidance, where it sets within minutes to form a stable three-dimensional scaffold.

The mechanism is cell-free. Rather than introducing cells from a laboratory, the scaffold works by matrix-induced chondrogenesis: once in place, it attracts the patient's own progenitor cells from the surrounding tissue and subchondral bone into the defect, providing the structural framework they need to lay down hyaline-like cartilage. No biopsy, no culture period, and no second procedure are required.

Published evidence for hip application exists. A 2021 study by Perez-Carro et al. (PMC8322278) reported arthroscopic delivery for hip chondral defects, with modified Harris Hip Score improvements of approximately 30 points — results in a similar range to those seen in other hip cartilage restoration series. Comparative long-term data specific to the hip joint remain limited, and defect characteristics confirmed at assessment will determine whether ChondroFiller injection is appropriate for a given patient.

Pricing is determined by the number of boxes required to fill the defect — not by which joint is treated. London Cartilage Clinic, which was the first UK clinic to offer ChondroFiller as a standalone injection under Professor Paul Y. F. Lee, publishes all-inclusive tariffs: £3,000 for one box, £5,500 for two, and £8,000 for three. The treatment is not commissioned by the NHS for the hip, and is not currently covered by Bupa or AXA for this indication. Lincolnshire Hip offers the ChondroFiller injection pathway for the hip alongside AMIC, and assessment determines which is more appropriate.

AMIC: single-stage surgery for larger focal defects

Plain microfracture — subchondral perforation alone — releases bone marrow stem cells and growth factors into a cartilage defect, but the repair tissue it produces is predominantly fibrocartilage, which tends to break down within two to three years and can damage the subchondral bone plate in ways that complicate any subsequent procedure. AMIC addresses this directly. The same microfracture step is performed, but immediately afterwards a bioresorbable collagen I/III membrane is pressed and fixed over the defect to stabilise the marrow clot and provide a structured scaffold for the incoming cells. The result is a single-stage operation — one anaesthetic, one recovery — rather than the two-stage process required by autologous chondrocyte implantation.

The current evidence base is substantial for a hip-specific technique. A 2025 systematic review and meta-analysis pooled results from 12 published papers covering 628 hips, with a weighted mean patient age of 35.8 years and a weighted mean defect size of 3.3 cm². The pooled success rate for AMIC was 99.6%, and the mean improvement on the modified Harris Hip Score was 35.8 points — marginally ahead of autologous chondrocyte transplantation (ACT) in the same analysis. That said, the review is not a randomised controlled trial, and UK-specific long-term outcome data for hip AMIC remain limited; findings should be interpreted with that in mind.

Eligibility is defined by defect characteristics and overall joint condition. AMIC is indicated for full-thickness symptomatic Grade 3–4 chondral defects measuring ≥2 cm², in patients whose hip joint space is still substantially preserved — conventionally Tönnis Grade 0 or 1. Once Tönnis Grade 2 or greater osteoarthritis is present, cartilage repair procedures are generally considered ineffective.

NICE has approved the AMIC technique — a useful credibility marker, though that approval does not create an NHS commissioning pathway for the hip. Private UK cost is approximately £7,000–£12,500 depending on the clinic and fee structure. Both Lincolnshire Hip and London Cartilage Clinic offer AMIC for focal hip cartilage defects; suitability relative to ChondroFiller injection is determined at assessment.

OATS: autograft plug transfer in the hip

OATS works on a straightforward principle: cylindrical plugs of bone and cartilage are harvested from a low-load area of the patient's own joint and press-fitted into the focal defect in a single operation. Because the transferred tissue is genuine hyaline cartilage from the same patient, there is no donor procurement, no laboratory culture stage, and no second procedure. The technique is best suited to defects of approximately 2 cm² or smaller in patients under 50 who retain good surrounding cartilage and a mechanically sound joint.

At the hip, however, OATS is substantially harder to deliver than at the knee or ankle. The deep, concave ball-and-socket geometry of the hip joint restricts instrument access and makes achieving the correct angles for plug harvesting and seating genuinely difficult. This is not a minor technical detail: it is why OATS for the hip is rarely performed in the UK even at specialist cartilage centres. All-inclusive private cost at London Cartilage Clinic is £14,000, covering theatre, the surgical fee, a consultant anaesthetist, and 12-month follow-up.

Wherever OATS is performed — hip or knee — donor-site morbidity deserves an honest mention. The site from which the plugs are harvested can produce localised discomfort or stiffness during the recovery period. For most patients this settles, but it is a meaningful consideration and should be discussed at consultation rather than treated as a footnote.

OATS is the autograft option in this pathway. When autograft is not technically feasible — as the hip's anatomy sometimes dictates — osteochondral allograft (OCA) using donor tissue is the step that follows.

OCA: allograft reconstruction for complex or large defects

Where autograft cannot cover the defect — because it is too large, too deep, or situated in a position the hip's tight anatomy makes inaccessible — OCA fills the gap using donor bone-and-cartilage tissue. A fresh osteochondral allograft preserves the structural relationship between the cartilage surface and its underlying bone, allowing reconstruction of defects that would exhaust the available autograft supply or impose unacceptable donor-site morbidity on the patient.

The additional steps involved — donor tissue procurement, cold-chain storage, and compliance with UK human tissue legislation — account for most of the cost differential. At London Cartilage Clinic, OCA is priced at £28,000 all-inclusive, covering theatre time, the donor tissue itself, and the regulatory framework required under UK law. That makes it the most expensive of the four private hip cartilage options, and also the rarest.

Long-term follow-up data exist — studies by Gross (2008) and Levy (2013) document durable outcomes in allograft recipients — but those datasets are drawn predominantly from the knee. Hip-specific OCA evidence remains more limited, and outcome expectations should be held with that in mind.

In practice, OCA tends to become the appropriate consideration when defect size exceeds approximately 4 cm², when structural complexity rules out both AMIC and autograft transfer, or in younger patients with significant posttraumatic cartilage loss where the joint surface requires reconstruction rather than incremental repair. It is not a first-line choice — it is the option that makes cartilage preservation possible when nothing less invasive can reach the whole defect.

Which option fits which patient — and how assessment works

The four options form a practical ladder ordered by invasiveness and cost, but a patient's defect rarely sits neatly on a single rung. Defect size matters — but so does depth, location within the hip joint, the integrity of the surrounding cartilage, subchondral bone quality, residual joint space, and what the patient expects to return to. These are anatomy-led findings, not preference settings.

For smaller focal defects with stable cartilage margins and a preserved joint space, ChondroFiller injection — an ultrasound-guided outpatient procedure from £3,000 — is often the appropriate starting point. Where defect size reaches 2 cm² or above and the subchondral bone requires stimulation, AMIC (£7,000–£12,500) offers a single-stage surgical route. The hip's constrained geometry then narrows the field further: OATS (£14,000) suits smaller defects in younger patients where autograft harvest is technically feasible; OCA (£28,000) is reserved for defects too large or structurally complex for the preceding options to address.

When a defect sits on the boundary between two rungs — a 2 cm² lesion in a very active patient, or a defect whose location makes autograft access uncertain — imaging characterisation is what makes a treatment recommendation clinically defensible rather than speculative. An MRI, and in some cases a motion or open-bore study, is typically the step between symptom recognition and any meaningful technique discussion. No published randomised controlled trial has directly compared these four techniques head-to-head in the hip; in boundary cases especially, the decision comes down to a detailed assessment conversation, not a published algorithm. Lincolnshire Hip, part of the MSK Doctors group, accepts patients without GP referral at Sleaford and Grantham — for anyone navigating the NHS gap this article describes, that assessment is where an informed answer begins.

1. [1] Outcomes of ACT and AMIC in the hip: a systematic review and meta-analysis. (2025). https://doi.org/10.1186/s13018-025-05862-5 https://doi.org/10.1186/s13018-025-05862-5
2. [2] Arthroscopic treatment of chondral defects in the hip: AMIC, MACI, MATT and other options. (2017). https://doi.org/10.1051/sicotj/2017029 https://doi.org/10.1051/sicotj/2017029
3. [3] Trends in Cartilage Repair Techniques for Chondral Defects in the Hip in Germany 2006–2022. (2024). https://doi.org/10.3390/life14101262 https://doi.org/10.3390/life14101262